Brass Moth / information services

Services

Guides, comparisons, and research summaries for people trying to understand ibogaine half-life—and why claims of a months-long “reset” need pharmacology, evidence, and caution kept in the same frame.

Symbolic still life reflecting the long tail of ibogaine and noribogaine effects

What these pages do

Separate the long tail from the long claim.

Ibogaine is metabolized to noribogaine, a compound often described as longer-acting. That pharmacokinetic detail is relevant, but it does not by itself prove that any reported change will persist for months. The core explainer on ibogaine’s extended effects keeps the distinction visible: drug presence, subjective experience, behavior, and lasting outcomes are related questions—not interchangeable ones.

Brass Moth is an independent resource on ibogaine, noribogaine, and claims of lasting change. The work is guided by our stated scope and editorial principles: plain language, evidence before claims, risk transparency, and respect for uncertainty. It is not clinical care, a referral service, or a promise of an outcome.

Abstract image accompanying the distinction between pharmacology and claims of lasting change

Start with the vocabulary.

Half-life is a measure of how concentrations decline over time; it is not a countdown for healing, recovery, or safety. A glossary-led approach helps separate ibogaine from noribogaine, acute effects from later reports, and drug metabolism from broader claims about a “reset.” The general idea of half-life in pharmacokinetics is useful here precisely because it describes concentration change, not a guaranteed personal result.

That distinction also matters for risk. The U.S. Food and Drug Administration has noted that ibogaine has been associated with serious adverse events, including cardiac risks. A long-acting metabolite is a reason for careful interpretation and safety questions—not a reason to convert duration into assurance.

“Lasting” is a claim that needs its own evidence. It cannot be borrowed from a half-life number.

Four working tools, cut for careful reading.

Each is an information service for sorting language, evidence, comparisons, and limits around ibogaine’s proposed months-long reset.

Pharmacokinetic guides

Plain-language guides map how ibogaine and noribogaine are discussed over time, without turning metabolism into a treatment promise. They pair naturally with questions such as what ibogaine therapy means in practice and what the term leaves unresolved.

Claim comparisons

Comparison notes pull apart the phrases people encounter: “reset,” interruption, reduced craving, after-effects, and durable change. They also make room for the difference between reported ibogaine therapy benefits and evidence strong enough to support a broad conclusion.

Decision frameworks

Practical question sets help readers assess marketing language, location-specific claims, and missing safety context. That includes asking what is being implied by searches for the best ibogaine treatment centers or by claims about ibogaine treatment in Texas, without endorsing any provider.

Risk and uncertainty summaries

Research summaries keep adverse effects, contraindication concerns, and gaps in evidence close to the claims they qualify. Readers looking into possible long-term side effects can use this frame to distinguish what is known, what is reported, and what remains uncertain.

A proof list for claims that travel fast.

Some questions begin with names, plants, or where a treatment might be available. Those starting points can be useful, but they are not evidence of effectiveness or safety. A clear account should say what substance is being discussed, what kind of outcome is claimed, what timeframe is meant, and what risks were left out.

For example, vocabulary around ibogaine street names can signal how informal terminology changes meaning, while background on plants associated with ibogaine helps distinguish botanical origin from a claim about a prepared substance. Likewise, asking where ibogaine treatment is available should not substitute for asking whether a specific claim has credible support.

×Is the claim describing a drug concentration, an acute experience, or a later behavior?
×Does it identify noribogaine without implying that duration equals benefit?
×Are safety limits, cardiac concerns, and uncertainty placed beside the promise?
×Is a personal report being presented as if it were durable evidence?

Loose pages / FAQ

Does a long half-life prove a lasting reset?

No. A long-lived metabolite can help explain why effects may extend beyond the acute experience, but it does not establish a durable outcome for an individual. The question of how much drug remains, the question of how someone feels, and the question of whether a change lasts are different layers of evidence.

Are these medical services?

No. Brass Moth provides independent information services: guides, comparisons, research summaries, and practical questions for evaluating claims and risks. It does not provide medical assessment, treatment, referrals, or legal advice.

Why keep safety in a page about duration?

Because duration claims can sound reassuring when they should prompt more questions. The practical limits around duration and safety belong in the same conversation as pharmacokinetics, especially when a substance is associated with serious adverse-event concerns.

Follow the mechanism, then question the promise.

For a focused map of ibogaine, noribogaine, and the language used to explain a months-long reset, continue through the pharmacokinetics overview and keep uncertainty in view.

Trace the proposed mechanisms →